PARADIGM-HF trial: will LCZ696 change the current treatment of systolic heart failure? J Geriatr Cardiol. 2015; 12 (5):470–473.Kaplinsky E. PARADIGM-HF Trial: will LCZ696 change the current treatment of systolic heart failure? J Geriatr Car- diol 2015; 12: 470-473.Kaplinsky E, PARADIGM...
The paper described simply the PARADIGM-HF(prospective comparison of ARNI with ACEI to determine impact on global mortality and morbidity in HF trial), and the results showed that comparing with the enalapril group, LCZ696(ARNI) reduced significantly primary endpoint(cardiovascular death or ...
3. Effects of Sacubitril/Valsartan in the PARADIGM-HF Trial (Prospective Comparison of ARNI with ACEI to Determine Impact on Global Mortality and Morbidity in Heart Failure) According to Background Therapy[J].Okumura; Naoki;Jhund; Pardeep S.;Gong; Jianjian;Lefkowitz; Martin P.;Rizkala; Ad...
We studied the frequency and prognostic importance of these episodes of worsening in the Prospective Comparison of ARNI (angiotensin-receptor-neprilysin inhibitor) with ACEI (angiotensin-converting enzyme inhibitor) to Determine Impact on Global Mortality and Morbidity in Heart Failure Trial (PARADIGM-HF)...
Clinical trials, such as the Stimulation of the Anterior Nucleus of the Thalamus for Epilepsy (SANTE) trial, have demonstrated significant seizure reductions with DBS, and emerging closed-loop systems promise even more precise control [34, 35]. Another groundbreaking advancement in epilepsy management...
outcomes (and the effect of sacubitril/valsartan) according to etiology in the PARADIGM-HF (Prospective comparison of angiotensin-receptor-neprilysin inhibitor [ARNI] with angiotensin-converting-enzyme inhibitor [ACEI] to Determine Impact on Global Mortality and morbidity in Heart Failure) trial. ...
This finding comes from the PARADIGM‑HF trial, which was presented at the ESC Congress 2014 in Barcelona, Spain and simultaneously published in The New England Journal of Medicine. ACE inhibitors have been the foundation of treatment for patients with HF with reduced ejection fraction (HFrEF) ...
Ongoing RCTs (SAVEPACe, DAVID II, INTRINSIC, MVP Trial) test the hypothesis that preservation of normal ventricular conduction by avoiding unnecessary RVA pacing reduces the risk of AF, HF, and death during pacemaker and ICD therapy. With respect to alternate site pacing, new tools are required...
Li DK, Paty DW 1999 Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relaps- ing-remitting multiple sclerosis. Prevention of relapses and disability by interferon- beta1a subcutaneously in multiple sclerosis. Ann ...
Regulatory T cells and T helper 17 cells are two recently described lymphocyte subsets with opposing actions. In this review, we discuss the mechanisms that promote development of these cells from common precursors and the specific factors that impact th